RxDoctor Payments Data

Muhammad Raqeem, MD

Hospitalist · Decatur, ILNPI 1598050494

Payments from drug & device makers

$1,457in general payments, 2019–2025

Across 64 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$427
  • AbbVie$351
  • E.r. Squibb & Sons, L.L.C.$163
  • Advanced Respiratory, Inc$78
  • Novartis$77
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$67
  • plus $293 from 10 others

What the payments were for

  • Food & beverage$1,40696%
  • Education$514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,457 in reported general payments places this provider in the 90th percentile of 1,328 hospitalist providers in Illinois.

See all hospitalist providers in Illinois

Medicare billing

Part B allowed, 2024
$120,118
Medicare patients
490
Services billed
1,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$51,132
EntrestoSacubitril/Valsartan18$7,348
JardianceEmpagliflozin13$5,164
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$3,795
Mesalamine13$3,502
TradjentaLinagliptin11$3,133
Levetiracetam48$2,128
Atorvastatin Calcium129$2,043
Scopolamine12$1,897
Midodrine Hcl17$1,870
Vilazodone Hcl12$1,807
Potassium Chloride65$1,524
Levothyroxine Sodium111$1,348
Amlodipine Besylate98$1,185
Metoprolol Succinate67$1,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$51,132142 claims
Boehringer IngelheimJardiance, Tradjenta$27$8,29724 claims
NovartisEntresto$77$7,34818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,328 hospitalist providers in Illinois.

Other hospitalist in Decatur

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →